The combined therapy of Montelukast plus H1-antihistamine for for moderate to severe Japanese cedar pollinosis and its clinical efficasy

The combined therapy of Montelukast plus H1-antihistamine for for moderate to severe Japanese cedar pollinosis and its clinical efficasy - The combined therapy of Montelukast plus H1-antihistamine tion for for for Japanese cedar pollinosis and its clinical efficasy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005121

Enrollment

180

Registered

2011-02-22

Start date

2011-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Japanese cedar pollinosis

Interventions

It is given montelukast 10mg plus loratadine 10 mg per 1 day, during Japanese pollen season. It is given montelukast 10mg plus placebo per 1 day, during Japanese pollen season. It is given montelukast

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Being over class 2 in CAP-RAST against Japanese Cedar pollen over, and having clinicalsymptoms during Japanese cedar pollen season.

Exclusion criteria

Exclusion criteria: Pregnancy, potential pregnancy, and breas-feeding patient.

Design outcomes

Primary

Measure	Time frame
The combined therapy of Montelukast plus H1-antihistamine	—

Secondary

Measure	Time frame
Nitric oxide consentration in upper airway	—

Countries

Japan

Contacts

Public ContactTakechiyo Yamada

Faculty of Medicine, University of Fukui Ororhinolaryngology, Head and Neck Surgery

ymdtkcy@gmail.com

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026